Cell Biology Techniques in COVID-19 Vaccine Developments

Shiyu Xie

doi:10.54254/2753-8818/2025.AU25998

Theoretical and Natural ScienceOpen access

Cell Biology Techniques in COVID-19 Vaccine Developments

Research Article

Open Access

Cell Biology Techniques in COVID-19 Vaccine Developments

Shiyu Xie ^1*

¹ Oregon Episcopal School

^*Corresponding author: xies@go.oes.edu

Published on 13 August 2025

TNS Vol.124

ISSN (Print): 2753-8826

ISSN (Online): 2753-8818

ISBN (Print): 978-1-80590-271-3

ISBN (Online): 978-1-80590-272-0

Download Cover

Abstract

With the outbreak of the COVID-19 pandemic, the SARS-CoV-2 virus began to spread rapidly, posing an unprecedented challenge to global public health. In the battle against the virus, the rapid development of vaccines and cell biology techniques has played a key role. They have enabled researchers to identify potential vaccine targets based on the cellular characteristics of the virus, thereby accelerating the vaccine development process. Currently, mRNA vaccines and viral vector vaccines have been put into use around the world, but they still face some technical challenges, especially long-term efficacy and immune escape. This paper analyzes the application of cell biology techniques in the development of COVID-19 vaccines and discusses the latest research progress from traditional cell culture techniques to mRNA and viral vector technologies. The research not only provides valuable references for future vaccine development but also reveals the shortcomings of current technologies in long-term immunity and production efficiency. Future research can further optimize these technologies, especially in the areas of vaccine scalability and immune responses.

Keywords:

COVID-19 vaccines, Cell biology techniques, mRNA vaccines.

View PDF

References

[1]. Wang, M.-Y., Zhao, R., Gao, L.-J., Gao, X.-F., Wang, D.-P., and Cao, J.-M. “SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development.” Frontiers in Cellular and Infection Microbiology, vol. 10, 2020.

[2]. Jackson, C. B., Farzan, M., Chen, B., and Choe, H. “Mechanisms of SARS-CoV-2 Entry into Cells.” Nature Reviews Molecular Cell Biology, vol. 23, no. 1, 2021, pp. 3–20.

[3]. Lou, Z., and Rao, Z. “The Life of SARS-CoV-2 Inside Cells: Replication–Transcription Complex Assembly and Function.” Annual Review of Biochemistry, vol. 91, no. 1, 2022, pp. 381–401.

[4]. Santos, V. R., Rodrigues, F., Sabino-Silva, R., and Carolina, A. “Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?” Frontiers in Microbiology, vol. 11, 2020.

[5]. “ACE2 & Functional Receptor for SARS Coronaviruses – Caltag Medsystems.” Caltagmedsystems.co.uk, 21 Apr. 2020, www.caltagmedsystems.co.uk/information/ace2-functional-receptor-for-sars-coronaviruses/.

[6]. Meng, J., Li, R., Zhang, Z., Wang, J., Huang, Q., Nie, D., Fan, K., Guo, W., Zhao, Z., and Han, Z. “A Review of Potential Therapeutic Strategies for COVID-19.” Viruses, vol. 14, no. 11, 2022, article 2346.

[7]. Howard, M. K., Kistner, O., and Barrett, P. N. “Pre-Clinical Development of Cell Culture (Vero)-Derived H5N1 Pandemic Vaccines.” Biological Chemistry, vol. 389, no. 5, 2008, pp. 569–577.

[8]. Cid, R., and Bolívar, J. “Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies.” Biomolecules, vol. 11, no. 8, 2021, article 1072.

[9]. Faria, R., Lucas, Su, Kobayashi, L. M., and Cristina, A. “Short Communication: Feasibility of Dengue Vaccine to Infect Different Human Cell Lines: An Alternative Potency Test Using HEK293T Cells.” PLoS ONE, vol. 17, no. 5, 2022, article e0267653.

[10]. Chavda, V., Bezbaruah, R., Valu, D., Patel, B., Kumar, A., Prasad, S., Kakoti, B., Kaushik, A., and Jesawadawala, M. “Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status.” Vaccines, vol. 11, no. 2, 2023, article 432.

[11]. Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., and Crommelin, D. J. A. “mRNA-Lipid Nanoparticle COVID-19 Vaccines: Structure and Stability.” International Journal of Pharmaceutics, vol. 601, 2021, article 120586.

References

[2]. Jackson, C. B., Farzan, M., Chen, B., and Choe, H. “Mechanisms of SARS-CoV-2 Entry into Cells.” Nature Reviews Molecular Cell Biology, vol. 23, no. 1, 2021, pp. 3–20.

[3]. Lou, Z., and Rao, Z. “The Life of SARS-CoV-2 Inside Cells: Replication–Transcription Complex Assembly and Function.” Annual Review of Biochemistry, vol. 91, no. 1, 2022, pp. 381–401.

[4]. Santos, V. R., Rodrigues, F., Sabino-Silva, R., and Carolina, A. “Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?” Frontiers in Microbiology, vol. 11, 2020.

[7]. Howard, M. K., Kistner, O., and Barrett, P. N. “Pre-Clinical Development of Cell Culture (Vero)-Derived H5N1 Pandemic Vaccines.” Biological Chemistry, vol. 389, no. 5, 2008, pp. 569–577.

[8]. Cid, R., and Bolívar, J. “Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies.” Biomolecules, vol. 11, no. 8, 2021, article 1072.

Cite this article

Xie,S. (2025). Cell Biology Techniques in COVID-19 Vaccine Developments. Theoretical and Natural Science,124,41-47.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

About volume

Volume title: Proceedings of ICBioMed 2025 Symposium: AI for Healthcare: Advanced Medical Data Analytics and Smart Rehabilitation

ISBN: 978-1-80590-271-3(Print) / 978-1-80590-272-0(Online)

Editor: Alan Wang

Conference website: https://2025.icbiomed.org/auckland.html

Conference date: 17 October 2025

Series: Theoretical and Natural Science

Volume number: Vol.124

ISSN: 2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).